HRP20040037A2 - 2 methyl-thieno-benzodiazepine lyophilized formulation - Google Patents

2 methyl-thieno-benzodiazepine lyophilized formulation Download PDF

Info

Publication number
HRP20040037A2
HRP20040037A2 HR20040037A HRP20040037A HRP20040037A2 HR P20040037 A2 HRP20040037 A2 HR P20040037A2 HR 20040037 A HR20040037 A HR 20040037A HR P20040037 A HRP20040037 A HR P20040037A HR P20040037 A2 HRP20040037 A2 HR P20040037A2
Authority
HR
Croatia
Prior art keywords
olanzapine
preparation according
approximately
preparation
disorders
Prior art date
Application number
HR20040037A
Other languages
English (en)
Croatian (hr)
Inventor
Kurt Douglas Dekemper
Alan Lee Fites
Steven Lamar Nail
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HRP20040037A2 publication Critical patent/HRP20040037A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HR20040037A 2001-07-20 2002-07-05 2 methyl-thieno-benzodiazepine lyophilized formulation HRP20040037A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30682901P 2001-07-20 2001-07-20
US38647402P 2002-06-07 2002-06-07
PCT/US2002/019799 WO2003007912A2 (en) 2001-07-20 2002-07-05 Lyophilized formulation comprising olanzapine

Publications (1)

Publication Number Publication Date
HRP20040037A2 true HRP20040037A2 (en) 2004-06-30

Family

ID=26975390

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040037A HRP20040037A2 (en) 2001-07-20 2002-07-05 2 methyl-thieno-benzodiazepine lyophilized formulation

Country Status (32)

Country Link
US (1) US20040176357A1 (cs)
EP (1) EP1423124B1 (cs)
JP (1) JP2004537546A (cs)
KR (1) KR20040017330A (cs)
CN (1) CN1537007A (cs)
AR (1) AR036180A1 (cs)
AT (1) ATE369137T1 (cs)
AU (1) AU2002320134B2 (cs)
BR (1) BR0211250A (cs)
CA (1) CA2448724A1 (cs)
CO (1) CO5540279A2 (cs)
CY (1) CY1107759T1 (cs)
CZ (1) CZ200484A3 (cs)
DE (1) DE60221674T2 (cs)
DK (1) DK1423124T3 (cs)
EA (1) EA006506B1 (cs)
ES (1) ES2289126T3 (cs)
HR (1) HRP20040037A2 (cs)
HU (1) HUP0401157A3 (cs)
IL (1) IL159098A0 (cs)
MX (1) MXPA04000541A (cs)
MY (1) MY135452A (cs)
NZ (1) NZ529667A (cs)
PE (1) PE20030281A1 (cs)
PL (1) PL366614A1 (cs)
PT (1) PT1423124E (cs)
SI (1) SI1423124T1 (cs)
SK (1) SK182004A3 (cs)
SV (1) SV2003001179A (cs)
UA (1) UA80095C2 (cs)
WO (1) WO2003007912A2 (cs)
ZA (1) ZA200400798B (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003300324A1 (en) * 2002-12-24 2004-07-22 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
AR047459A1 (es) 2004-01-27 2006-01-18 Synthon Bv Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina)
WO2006076124A2 (en) * 2004-12-16 2006-07-20 Nektar Therapeutics Stable, non-crystalline formulation comprising olanzapine
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
JP2021509677A (ja) * 2018-01-05 2021-04-01 インペル ニューロファーマ インコーポレイテッド 精密嗅覚装置によるオランザピンの鼻孔間送達
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
CN115006406A (zh) * 2021-12-28 2022-09-06 南京清普生物科技有限公司 一种稳定的奥氮平制剂
WO2025056094A1 (zh) * 2023-09-15 2025-03-20 广州帝奇医药技术有限公司 一种冻干制剂和注射液及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69004921T2 (de) * 1989-09-30 1994-05-05 Eisai Co Ltd Injizierbare Cephalosporinpräparate und ihre Anwendung.
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Also Published As

Publication number Publication date
EP1423124B1 (en) 2007-08-08
US20040176357A1 (en) 2004-09-09
IL159098A0 (en) 2004-05-12
CN1537007A (zh) 2004-10-13
PE20030281A1 (es) 2003-03-27
MXPA04000541A (es) 2004-05-04
KR20040017330A (ko) 2004-02-26
NZ529667A (en) 2006-02-24
SI1423124T1 (sl) 2008-02-29
CY1107759T1 (el) 2013-06-19
JP2004537546A (ja) 2004-12-16
WO2003007912A2 (en) 2003-01-30
CO5540279A2 (es) 2005-07-29
AR036180A1 (es) 2004-08-18
EA200400211A1 (ru) 2004-06-24
HK1066484A1 (en) 2005-03-24
MY135452A (en) 2008-04-30
SV2003001179A (es) 2003-07-29
DE60221674D1 (de) 2007-09-20
DK1423124T3 (da) 2007-12-03
AU2002320134B2 (en) 2007-04-05
UA80095C2 (en) 2007-08-27
EP1423124A2 (en) 2004-06-02
PT1423124E (pt) 2007-10-29
CZ200484A3 (cs) 2005-01-12
HUP0401157A2 (hu) 2004-10-28
ATE369137T1 (de) 2007-08-15
BR0211250A (pt) 2004-07-27
EA006506B1 (ru) 2005-12-29
SK182004A3 (en) 2004-09-08
ES2289126T3 (es) 2008-02-01
PL366614A1 (en) 2005-02-07
HUP0401157A3 (en) 2008-01-28
CA2448724A1 (en) 2003-01-30
ZA200400798B (en) 2005-07-27
DE60221674T2 (de) 2008-04-30
WO2003007912A3 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
US11446310B2 (en) Stable formulations for parenteral injection of small molecule drugs
JP5406197B2 (ja) ダントロレン治療剤の送達を改善するための、共溶媒組成物および方法
US20040224942A1 (en) Use of N-desmethylclozapine to treat human neuropsychiatric disease
HRP20040037A2 (en) 2 methyl-thieno-benzodiazepine lyophilized formulation
MX2008011993A (es) Formulaciones para administracion parenteral de compuestos y sus usos.
Jones et al. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms
AU2002320134A1 (en) Lyophilized formulation comprising olanzapine
KR20180048707A (ko) 중환자 치료 동안 사용을 위한 진정제 및 비경구 제제의 방법들
Bernardi et al. Effects of abrupt and gradual withdrawal from long-term haloperidol treatment on open field behavior of rats
HK1066484B (en) Lyophilized formulation comprising olanzapine
Rampello et al. Nicergoline facilitates vestibular compensation in aged male rats with unilateral labyrinthectomy
JP5557409B2 (ja) （ｓ）−２−（ベンジルアミノメチル）−２，３，８，９−テトラヒドロ−７ｈ−１，４−ジオキシノ（２，３）ｅインドール−８−オンと神経遮断薬との組合せ
JPH04235134A (ja) 呼吸困難を処置するのに用いるための治療剤
TW202523318A (zh) 聯合治療腫瘤的藥物
JPH04243836A (ja) 急性非リンパ性白血病治療剤
CN107913253A (zh) 注射用乙酰谷酰胺冻干粉针剂及其制备方法
HK1204771B (en) Stable formulations for parenteral injection of small molecule drugs

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20080630

Year of fee payment: 7

OBST Application withdrawn